Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 421-434 , September 2006

Initial work-up and long-term follow-up in patients with phaeochromocytomas and paragangliomas

  • Pierre-François Plouin (Professor of Vascular Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +33 1 56 09 37 73; Fax: +33 1 56 09 37 91.

References 

  1. Lenders JW, Eisenhofer G, Mannelli M, et al. Phaeochromocytoma. Lancet. 2005;366:665–675
  2. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocrine Reviews. 2003;24:539–553
  3. La Batide-Alanore A, Chatellier G, Plouin PF. Diabetes as a marker of pheochromocytoma in hypertensive patients. Journal of Hypertension. 2003;21:1703–1707
  4. Amar L, Servais A, Gimenez-Roqueplo AP, et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. The Journal of Clinical Endocrinology and Metabolism. 2005;90:2110–2116
  5. Mansmann G, Lau J, Balk E, et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocrine Reviews. 2004;25:309–340
  6. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian society of endocrinology. The Journal of Clinical Endocrinology and Metabolism. 2000;85:637–644
  7. Crout JR, Sjoerdsma A. Turnover and metabolism of catecholamines in patients with pheochromocytoma. The Journal of Clinical Investigation. 1964;43:94–102
  8. Eisenhofer G, Keiser H, Friberg P, et al. Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. The Journal of Clinical Endocrinology and Metabolism. 1998;83:2175–2185
  9. Plouin PF, Duclos JM, Ménard J, et al. Biochemical tests for diagnosis of phaeochromocytoma: urinary versus plasma determinations. British Medical Journal. 1981;282:853–854
  10. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best?. The Journal of the American Medical Association. 2002;287:1427–1434
  11. Kudva YC, Sawka AM, Young WF. Clinical review 164. The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. The Journal of Clinical Endocrinology and Metabolism. 2003;88:4533–4539
  12. Héron E, Chatellier G, Billaud E, et al. The urinary metanephrine to creatinine ratio in the diagnosis of pheochromocytoma. Annals of Internal Medicine. 1996;125:300–303
  13. Guller U, Turek J, Eubanks S, et al. Detecting pheochromocytoma: defining the most sensitive test. Annals of Surgery. 2006;243:102–107
  14. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. The Journal of Clinical Endocrinology and Metabolism. 2003;88:2656–2666
  15. Eisenhofer G. Free or total metanephrines for diagnosis of pheochromocytoma: what is the difference?. Clinical Chemistry. 2001;47:988–989
  16. Esler M, Alvarenga M, Lambert G, et al. Cardiac sympathetic nerve biology and brain monoamine turnover in panic disorder. Annals of the New York Academy of Sciences. 2004;1018:505–514
  17. Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Annals of Internal Medicine. 2001;134:315–329
  18. Azizi M, Day M, Plouin PF. Localizing value of catecholamine profile in patients with adrenal or ectopic pheochromocytoma. The American Journal of Hypertension. 1994;7:110–111
  19. Des Senanayake P, Denker J, Bravo EL, et al. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. The Journal of Clinical Investigation. 1995;96:2503–2509
  20. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. The New England Journal of Medicine. 2003;348:1134–1149
  21. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. The Journal of Clinical Endocrinology and Metabolism. 1997;82:2622–2628
  22. d'Herbomez M, Gouze V, Huglo D, et al. Chromogranin A assay and (131)I-MIBG scintigraphy for diagnosis and follow-up of pheochromocytoma. Journal of Nuclear Medicine. 2001;42:993–997
  23. Baudin E, Gigliotti A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. British Journal of Cancer. 1998;78:1102–1107
  24. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. Journal of Clinical Oncology. 2005;23:8812–8818
  25. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. The Journal of Clinical Endocrinology and Metabolism. 2004;89:479–491
  26. Maurea S, Cuocolo A, Reynolds JC, et al. Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. Quarterly Journal of Nuclear Medicine. 1996;40:365–371
  27. Brink I, Hoegerle S, Klisch J, et al. Imaging of pheochromocytoma and paraganglioma. Familial Cancer. 2005;4:61–68
  28. van den Berg R. Imaging and management of head and neck paragangliomas. European Radiology. 2005;15:1310–1318
  29. Glowniak JV, Kilty JE, Amara SG, et al. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. Journal of Nuclear Medicine. 1993;34:1140–1146
  30. Furuta N, Kiyota H, Yoshigoe F, et al. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. International Journal of Urology. 1999;6:119–124
  31. Nguyen HH, Proye CA, Carnaille B, et al. Tumour size: the only predictive factor for 131I MIBG uptake in phaeochromocytoma and paraganglioma. Australian and New Zealand Journal of Surgery. 1999;69:350–353
  32. Bustillo A, Telischi F, Weed D, et al. Octreotide scintigraphy in the head and neck. The Laryngoscope. 2004;114:434–440
  33. Adams S, Baum RP. Intraoperative use of gamma-detecting probes to localize neuroendocrine tumors. Quarterly Journal of Nuclear Medicine. 2000;44:59–67
  34. Eisenhofer G, Bornstein SR, Brouwers FM, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancer. 2004;11:423–436
  35. Shapiro B, Sisson JC, Lloyd R, et al. Malignant phæochromocytoma: clinical, biochemical and scintigraphic characterization. Clinical Endocrinology. 1984;20:189–203
  36. Orchard T, Grant CS, van Heerden JA, et al. Pheochromocytoma – continuing evolution of surgical therapy. Surgery. 1993;114:1153–1158
  37. Goldstein RE, O'Neill JA, Holcomb GW, et al. Clinical experience over 48 years with pheochromocytoma. Annals of Surgery. 1999;229:755–764
  38. John H, Ziegler WH, Hauri D, et al. Pheochromocytomas: can malignant potential be predicted?. Urology. 1999;53:679–683
  39. Khorram-Manesh A, Ahlman H, Nilsson O, et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. Journal of Internal Medicine. 2005;258:55–66
  40. Plouin PF, Chatellier G, Fofol I, et al. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension. 1997;29:1133–1139
  41. van der Harst E, de Herder WW, de Krijger RR, et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. European Journal of Endocrinology. 2002;147:85–94
  42. Tippett PA, West RS, McEwan AJ, et al. A comparison of dopamine and homovanillic acid excretion as prognostic indicators in malignant phaeochromocytoma. Clinica Chimica Acta. 1987;166:123–133
  43. Eisenhofer G, Goldstein DS, Sullivan P, et al. Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine. The Journal of Clinical Endocrinology and Metabolism. 2005;90:2068–2075
  44. Mannelli M, Ianni L, Cilotti A, et al. Pheochromocytoma in Italy: a multicentric retrospective study. European Journal of Endocrinology. 1999;141:619–624
  45. Brouwers FM, Petricoin EF, Ksinantova L, et al. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocrine-Related Cancer. 2005;12:263–272
  46. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. The Journal of Clinical Endocrinology and Metabolism. 2001;86:5658–5671
  47. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet. 2003;361:2059–2067
  48. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. The Journal of the American Medical Association. 1997;278:51–57
  49. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clinic Proceedings. 1999;74:543–552
  50. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. The Journal of Clinical Endocrinology and Metabolism. 2001;86:4041–4046
  51. Manger WM, Gifford RW. Pheochromocytoma: a clinical overview. In:  Laragh JH,  Brenner BM editor. 2nd edn.. Hypertension: Pathophysiology, Diagnosis and Management. New York: Raven Press; 1995;p. 2225–2244
  52. Knudson AG. Antioncogenes and human cancer. Proceedings of the National Academy of Sciences of the USA. 1993;90:10914–10921
  53. Baysal BE. On the association of succinate dehydrogenase mutations with hereditary paraganglioma. Trends in Endocrinology and Metabolism. 2003;14:453–459
  54. Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. The New England Journal of Medicine. 2002;346:1459–1466
  55. Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Research. 2003;63:5615–5621
  56. Neumann HP, Pawlu C, Peczkowska M, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. The Journal of the American Medical Association. 2004;292:943–951
  57. Plouin PF, Gimenez-Roqueplo AP. The genetic basis of pheochromocytoma: who to screen and how?. Nature Clinical Practice. Endocrinology and Metabolism. 2006;2:60–61
  58. Plouin PF, Duclos JM, Soppelsa F, et al. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. The Journal of Clinical Endocrinology and Metabolism. 2001;86:1480–1486
  59. Chew SL. Recent developments in the therapy of phaeochromocytoma. Expert Opinion on Investigational Drugs. 2004;13:1579–1583
  60. Shen WT, Sturgeon C, Clark OH, et al. Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery. 2004;136:1129–1137
  61. Hwang J, Shoaf G, Uchio EM, et al. Laparoscopic management of extra-adrenal pheochromocytoma. The Journal of Urology. 2004;171:72–76
  62. Diner EK, Franks ME, Behari A, et al. Partial adrenalectomy: the National Cancer Institute experience. Urology. 2005;66:19–23
  63. Bravo EL, Tarazi RC, Gifford RW, et al. Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. The New England Journal of Medicine. 1979;301:682–686
  64. van der Harst E, de Herder WW, Bruining HA, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. The Journal of Clinical Endocrinology and Metabolism. 2001;86:685–693
  65. Mayo C. Paroxysmal hypertension with tumor of retroperitoneal nerve. The Journal of the American Medical Association. 1927;139:1047–1050
  66. Streeten DHP, Anderson GH, Wagner S. Effect of age on response of secondary hypertension to specific treatment. The American Journal of Hypertension. 1990;3:360–365
  67. Amar L, Peyrard S, Rossignol P et al. The course of urinary metanephrine excretion in recurrent and malignant pheochromocytomas and secreting paragangliomas. Annals of the New York Academy of Sciences [in press].
  68. Takahashi K, Ashizawa N, Minami T, et al. Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. Internal Medicine. 1999;38:349–354
  69. San Millan Ruiz D, Burkhardt K, Jean B, et al. Pathology findings with acrylic implants. Bone. 1999;25(supplement):85S–90S
  70. Steinsapir J, Carr AA, Prisant LM, et al. Metyrosine and pheochromocytoma. Archives of Internal Medicine. 1997;157:901–906

PII: S1521-690X(06)00050-9

doi: 10.1016/j.beem.2006.07.004

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 421-434 , September 2006

Article Tools

* Image Usage & Resolution